The role of thymidine kinase in cancer diseases.

Thymidine kinase 1 (TK 1-fetal) is a cell cycle-dependent marker that increases dramatically during the S-phase of the cell cycle. In this review, the authors discuss serum levels of thymidine kinase in a variety of neoplasias. Determination of thymidine kinase helps to monitor the follow-up of solid tumours and haematological malignancies as well as indicating the efficacy of adjuvant and palliative chemotherapy. Elevated levels of thymidine kinase must always be interpreted together with a detailed knowledge of the patient's condition because nonspecific elevations of serum levels (inflammatory and autoimmune diseases) must be excluded.

[1]  H. Vesselle,et al.  A simple quantitative assay for the activity of thymidine kinase 1 in solid tumors. , 2007, Nuclear medicine and biology.

[2]  J. Finek,et al.  Tumor markers in patients with relapse of colorectal carcinoma. , 2007, Anticancer research.

[3]  O. Topolcan,et al.  Prognostic importance of thymidine kinase in colorectal and breast cancer. , 2007, Anticancer research.

[4]  O. Topolcan,et al.  Dynamics of serum levels of tumour markers and prognosis of recurrence and survival after liver surgery for colorectal liver metastases. , 2007, Anticancer research.

[5]  T. Hájek,et al.  Tumor markers in pleural effusions. , 2007, Anticancer research.

[6]  O. Topolcan,et al.  Changes of serum thymidine kinase in children with acute leukemia. , 2007, Anticancer research.

[7]  M. Duffy,et al.  Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. , 2007, European journal of cancer.

[8]  N. Sardesai,et al.  Detection of Newly Diagnosed Bladder Cancer, Bladder Cancer Recurrence and Bladder Cancer in Patients with Hematuria Using Quantitative RT-PCR of Urinary Survivin , 2007, Tumor Biology.

[9]  M. Abrahamowicz,et al.  Disability Evolution in Multiple Sclerosis: How to Deal with Missing Transition Times in the Markov Model? , 2007, Neuroepidemiology.

[10]  H. Johansson,et al.  Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. , 2006, Anticancer research.

[11]  K. Itoh,et al.  Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[12]  M. Piccart,et al.  Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. , 2006, The oncologist.

[13]  Wei Zhang,et al.  Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. , 2006, Oncology reports.

[14]  R. Lamerz,et al.  Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. , 2005, Anticancer research.

[15]  L. Holubec,et al.  TPS, thymidine kinase, VEGF and endostatin in cytosol of thyroid tissue samples. , 2005, Anticancer research.

[16]  Staffan Eriksson,et al.  Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. , 2005, Oncology reports.

[17]  J. Castro,et al.  Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. , 2004, International journal of oncology.

[18]  Staffan Eriksson,et al.  Sensitive nonradiometric method for determining thymidine kinase 1 activity. , 2004, Clinical chemistry.

[19]  R. González-Sarmiento,et al.  Clinical value of p53, c‐erbB‐2, CEA and CA125 regarding relapse, metastasis and death in resectable non‐small cell lung cancer , 2003, International journal of cancer.

[20]  Seung-Ha Park,et al.  The Relationship between Serum VEGF Concentration and Prognosis of Lung Cancer , 2003, The Korean journal of internal medicine.

[21]  Otakar Belohlavek,et al.  Routine 18F-FDG PET Preoperative Staging of Colorectal Cancer: Comparison with Conventional Staging and Its Impact on Treatment Decision Making , 2003 .

[22]  M. Rocchi,et al.  Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer. , 2003, The International journal of biological markers.

[23]  C. Coca,et al.  Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer. , 2003, Anticancer research.

[24]  H. Kimura,et al.  Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer. , 2003, Anticancer research.

[25]  M. Kersten,et al.  Serum Soluble CD27, but Not Thymidine Kinase, Is an Independent Prognostic Factor for Outcome in Indolent Non-Hodgkin’s Lymphoma , 2003, Tumor Biology.

[26]  C. Tei,et al.  Clinical significance of serum neuron‐specific enolase in patients with adult T‐cell leukemia , 2002, American journal of hematology.

[27]  H. Katabuchi,et al.  Thymidine kinase in epithelial ovarian cancer: Relationship with the other pyrimidine pathway enzymes , 2002, International journal of cancer.

[28]  L Zou,et al.  The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. , 2002, The International journal of biological markers.

[29]  B. K. Murray,et al.  Thymidine kinase: diagnostic and prognostic potential , 2001, Expert review of molecular diagnostics.

[30]  H. Yeh,et al.  Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  H. Katabuchi,et al.  Clinical Value of Thymidine Kinase in Patients with Cervical Carcinoma , 2001, Oncology.

[32]  B Asselain,et al.  Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Kantarjian,et al.  Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. Foekens,et al.  Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. , 2001, Cancer research.

[35]  K. O’Neill,et al.  A monoclonal antibody specific for human thymidine kinase 1. , 2001, Hybridoma.

[36]  S. Eriksson,et al.  Investigation on Cell Proliferation with a New Antibody against Thymidine Kinase 1 , 2001, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[37]  O. Topolcan,et al.  The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence. , 2000, Anticancer research.

[38]  S. Eriksson,et al.  Cloning and characterization of full-length mouse thymidine kinase 2: the N-terminal sequence directs import of the precursor protein into mitochondria. , 2000, The Biochemical journal.

[39]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[40]  T. Fornander,et al.  The Clinical Significance of Thymidine Kinase 1 Measurement in Serum of Breast Cancer Patients Using Anti-TK1 Antibody , 2000, The International journal of biological markers.

[41]  E. Thiel,et al.  Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. , 1999, Blood.

[42]  S. Barnhill,et al.  CA 125: The past and the Future , 1998, The International journal of biological markers.

[43]  D. Dormont,et al.  Monitoring of intracellular levels of 5'-monophosphate-AZT using an enzyme immunoassay. , 1998, Journal of immunological methods.

[44]  M A Torkington,et al.  An evidence-based approach , 1998, British Dental Journal.

[45]  L. Kanz,et al.  Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. , 1998, Seminars in oncology.

[46]  M. Hallek,et al.  Serum thymidine kinase levels are elevated and exhibit diurnal variations in patients with advanced ovarian cancer. , 1997, Clinica chimica acta; international journal of clinical chemistry.

[47]  H. Pahl,et al.  Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma. , 1997, Anticancer research.

[48]  G. Sutton,et al.  Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma. , 1997, Anticancer research.

[49]  J. Foekens,et al.  DNA‐synthesis enzyme activity: A biological tool useful for predicting anti‐metabolic drug sensitivity in breast cancer? , 1997, International journal of cancer.

[50]  E. Wintersberger.  Regulation and biological function of thymidine kinase. , 1997, Biochemical Society transactions.

[51]  M. Hallek,et al.  Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. , 1996, Leukemia & lymphoma.

[52]  J. Robertson,et al.  Serum thymidine kinase in colorectal neoplasia. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[53]  S. Modoni,et al.  Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia , 1995, British journal of haematology.

[54]  O. Chinot,et al.  Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer , 1995, International journal of cancer.

[55]  B. Munch‐Petersen,et al.  Overexpression of human thymidine kinase mRNA without corresponding enzymatic activity in patients with chronic lymphatic leukemia. , 1994, Leukemia research.

[56]  J. Borovanský,et al.  Thymidine kinase in malignant melanoma , 1994, Melanoma research.

[57]  E. Wintersberger,et al.  Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. , 1994, The Journal of biological chemistry.

[58]  T. Aotake,et al.  [Prediction of prognosis of patients with gastrointestinal cancer based on thymidine uptake]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[59]  F. Naguib,et al.  Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. , 1993, Cancer research.

[60]  B. Munch‐Petersen,et al.  Reversible ATP-dependent transition between two forms of human cytosolic thymidine kinase with different enzymatic properties. , 1993, The Journal of biological chemistry.

[61]  Duen-Yi Huang,et al.  The regulation of thymidine kinase in HL-60 human promyeloleukemia cells. , 1993, The Journal of biological chemistry.

[62]  K. O’Neill,et al.  Can thymidine kinase levels in breast tumors predict disease recurrence? , 1992, Journal of the National Cancer Institute.

[63]  F. Spyratos,et al.  Multiparametric prognostic evaluation of biological factors in primary breast cancer. , 1992, Journal of the National Cancer Institute.

[64]  B. Emmerich,et al.  Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications , 1992, Annals of Hematology.

[65]  Kauffman Mg,et al.  Mutations in the thymidine kinase gene that allow expression of the enzyme in quiescent (G0) cells. , 1991 .

[66]  P. Lönnroth,et al.  Amiloride inhibits insulin sensitivity and responsiveness in rat adipocytes through different mechanisms. , 1991, Biochemical and biophysical research communications.

[67]  T. Kelly,et al.  Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis , 1991, Molecular and cellular biology.

[68]  B. Oberg,et al.  Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. , 1991, Biochemical and biophysical research communications.

[69]  A. S. Lee,et al.  Identification of a 70-base-pair cell cycle regulatory unit within the promoter of the human thymidine kinase gene and its interaction with cellular factors , 1991, Molecular and cellular biology.

[70]  S. Conrad,et al.  Independent regulation of thymidine kinase mRNA and enzyme levels in serum-stimulated cells. , 1990, The Journal of biological chemistry.

[71]  J. Gronowitz,et al.  Molecular forms in human serum of enzymes synthesizing DNA precursors and DNA , 1990, Molecular and Cellular Biochemistry.

[72]  G. Merrill,et al.  Thymidine kinase synthesis is repressed in nonreplicating muscle cells by a translational mechanism that does not affect the polysomal distribution of thymidine kinase mRNA. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[73]  M. Meuth,et al.  The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. , 1989, Experimental cell research.

[74]  F. Ruddle,et al.  Transcriptional and posttranscriptional mechanisms regulate murine thymidine kinase gene expression in serum-stimulated cells , 1988, Molecular and cellular biology.

[75]  D. Sheer,et al.  Construction of a genetic map of human chromosome 17 by use of chromosome-mediated gene transfer. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[76]  M. Hallek,et al.  Activity of serum thymidine kinase in non-Hodgkin lymphoma: Relationship to other prognostic factors , 1988, Klinische Wochenschrift.

[77]  D. Macphee,et al.  The role of blood platelets in nucleoside metabolism: assay, cellular location and significance of thymidine phosphorylase in human blood. , 1988, Mutation research.

[78]  J. Kausitz.  [Radioimmunoanalysis in oncology]. , 1988, Bratislavske lekarske listy.

[79]  J. Sherley,et al.  Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.

[80]  J. Sherley,et al.  Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. , 1988, The Journal of biological chemistry.

[81]  D. L. Coppock,et al.  Control of thymidine kinase mRNA during the cell cycle , 1987, Molecular and cellular biology.

[82]  K. Nilsson,et al.  Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia , 1987, European journal of haematology.

[83]  Broder,et al.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[84]  B Simonsson,et al.  Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia , 1984, Cancer.

[85]  B. Munch‐Petersen.  Differences in the kinetic properties of thymidine kinase isoenzymes in unstimulated and phytohemagglutinin-stimulated human lymphocytes , 1984, Molecular and Cellular Biochemistry.

[86]  H. Hagberg,et al.  The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. , 1983, British Journal of Cancer.

[87]  Y. Cheng,et al.  Human deoxythymidine kinase. I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia. , 1976, The Journal of biological chemistry.

[88]  B. Barbiroli,et al.  Thymidine kinase and deoxyribonucleic acid metabolism in growing and regenerating livers from rats on controlled feeding schedules. , 1973, The Biochemical journal.

[89]  O. Jones,et al.  Properties of thymidine kinase partially purified from human fetal and adult tissue. , 1972, The Journal of biological chemistry.

[90]  N. Fukui.  Factors regulating thymidine kinase in regenerating liver. , 1971, Journal of biochemistry.

[91]  Enrique Parás Chavero.  The past and the future , 1965 .

[92]  E. Kay,et al.  An Improved Preparation of Sodium Desoxyribonucleate , 1952 .

[93]  A. Chang.  Oncology : an evidence-based approach , 2006 .

[94]  S. Skog,et al.  Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. , 2005, Oncology reports.

[95]  O. Belohlávek,et al.  Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[96]  S. Tucker,et al.  Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. , 1995, Leukemia & lymphoma.

[97]  T. Kelly,et al.  Mutations in the thymidine kinase gene that allow expression of the enzyme in quiescent (G0) cells. , 1991, Oncogene.

[98]  P. McKenna,et al.  The Significance of Thymidine Kinase in Determining Resistance to Mutagenesis in Friend Mouse Leukemia Cells , 1991 .

[99]  S. Tadepalli,et al.  Determination of zidovudine concentration in serum by enzyme-linked immunosorbent assay and by time-resolved fluoroimmunoassay. , 1990, Journal of acquired immune deficiency syndromes.

[100]  P. Roberts.  Tumour markers in colorectal cancer. , 1988, Scandinavian journal of gastroenterology. Supplement.

[101]  P. Reichard,et al.  Reduction of ribonucleotides. , 1979, Annual review of biochemistry.

[102]  A. Kornberg,et al.  DEOXYTHYMIDINE KINASE OF ESCHERICHIA COLI. II. KINETICS AND FEEDBACK CONTROL. , 1964, The Journal of biological chemistry.